RUNX3 and colonic neoplasm: In summary, RUNX3 can inhibit the proliferation, migration, and invasion ability of human colorectal cancer HT-29, and its antineoplastic mechanism is through reducing the expression of MMP-2 and MMP-9, and ultimately inhibit the invasion and metastasis of colon cancer cells, but the pathway remains still unclear, which will also be our future research direction.